1 The abbreviations used are: TPA, phorbol 12-myristate 13-acetate; SK-Ecad, SKBR3-wild type E-cadherin transfected cells; 782∆6, E-cadherin with a 6-amino acid deletion; 791∆5, E-cadherin with a 5-amino acid deletion; 795∆5, E-cadherin with a 5-amino acid deletion; E-cad 100 , M r = 100,000 E-cadherin; E-cad 97 , M r = 97,000 E-cadherin. 
Introduction
The cadherin family of transmembrane glycoproteins mediates Ca 2+ -dependent intercellular adhesion in a homophilic manner (1) . The classical cadherins, including N-, P-, and Ecadherin are well-conserved and are structurally similar. The cadherin structure consists of an extracellular domain with five tandem repeats, a transmembrane domain, and a cytoplasmic domain that interacts with the catenin family binding proteins (2) . The inter-epithelial binding of E-cadherin, which mediates lateral cell-cell adhesion in secretory tissues such as the prostate and mammary gland (3) , results in the formation of desmosomes and adherins junctions that are required for tissue morphogenesis and maintenance of the differentiated phenotype (1) . The integrity of E-cadherin binding is dependent on its interaction with the catenin binding proteins in the intracellular domain. E-cadherin binds to β-, γ-and α-catenin (4), which physically associate with actin filaments and the actin cytoskeleton (5-7). Inactivation of E-cadherin through gene mutation, transcriptional inactivation, or promoter methylation has been demonstrated in many adenocarcinomas (8) (9) (10) (11) (12) (13) . However, these mechanisms are not likely to account for all mechanisms by which E-cadherin becomes inactivated in cancer.
One mechanism of E-cadherin inactivation involves the proteolytic ablation of the extracellular domain (14) . The generation of a soluble 80-kDa fragment that was shed into the medium of cultured cancer cells in response to calcium influx (15, 16) resulted from cleavage by a matrix metalloprotease activity (17, 18) . It was also demonstrated that metalloproteases mediated the cleavage of the extracellular domain of VE-cadherin that was shed into cultures of human endothelial cells (19) . Additionally, caspase-3 has recently been shown to cleave E-cadherin during the execution phase of apoptosis (20) . Taken together, these studies have demonstrated by guest on October 30, 2017 http://www.jbc.org/ Downloaded from that specific proteases can target and inactivate E-cadherin; however, the biological ramifications of these proteolytic mechanisms remain unknown.
We have previously identified a novel 97-kDa truncated E-cadherin species that may be important in localized prostate tumorigenesis (21) . We have since identified a novel E-cad 100 species that is generated by a calcium-dependent mechanism and may also be important in prostate tumor progression. Due to the apparent requirement of calcium in the generation of Ecad 100 , the calpain family of cysteine proteases emerged as a likely candidate mediating this cleavage event. There are two main isoforms of calpain that are ubiquitously expressed in tissue and are designated µ-and m-calpain based on the concentration of calcium required for their respective function in vitro (22) (23) (24) (25) . Because physiological concentrations of calcium are in the range of 100-300nM, it is hypothesized that other mechanisms exist to lower the activation threshold of calcium required for calpain activation in vivo (22, 24) . Calpains are heterodimeric proteins consisting of a large 80-kDa subunit that contains the regulatory and catalytic domains, and a smaller 29-kDa subunit, which is common to the two main isoforms. Calpain is involved in diverse physiologic roles including cell-cycle regulation (26, 27) , signal transduction (28) , and apoptosis (29) (30) (31) . Calpain proteolysis occurs in a limited fashion, producing distinct peptide fragments without further degradation (32) . Secondary structure is likely to affect substrate specificity, since many proteins contain consensus calpain sequences but are not susceptible to cleavage (32) . Proteins that have been identified as substrates of calpain include the cytoskeletal proteins spectrin and members of the integrin family (33, 34) .
In adenocarcinoma, the disruption of cellular adhesion appears to rise, in part, through alterations of the E-cadherin cell-adhersion system (35 SK-Ecad was generated by transfection of a plasmid that contained wild-type human E-cadherin in the pLK-pac vector with a 2X-myc epitope added to the last codon (gift of Dr. Margaret Wheelock) and was selected with puromycin. Transfection was done with Lipofectin (Life Technologies, Inc.) as instructed. E-cadherin mutants were generated from wild-type human Ecadherin cDNA cloned into the pcDNA3 vector that contained a 2X-myc epitope added to the last codon. Transfections with pcDNA3-based vectors were done with the FuGene 6 transfection reagent (Roche Biochemicals) and selected with G418.
Western Analysis and Immunoprecipitations -Protein lysates were prepared from tissue and cultured cells in the following buffer: 50mM Tris, pH 7.5, 120mM NaCl, 0.5% Nonidet p-40, 40µ
M PMSF (phenylmethylsulfonyl fluoride), 50 µg/ml leupeptin, 50 µg/ml aprotinin, 200 µM orthovanadate, 1mM EGTA. Tissue was homogenized prior to lysing. Cells were allowed to lyse 1hr on ice, centrifuged, supernatants extracted, and quantitated using a Bradford assay. Lysates were separated by 6% Novex gels and analyzed using chemiluminescence (Amersham Pharmacia Biotech) as described previously (36) . Membranes were stripped with the following stripping solution: 62.5mM Tris pH 6.8, 2% SDS, 100mM BME. Following ECL and washing, the membrane was incubated with the stripping solution for 30 min at 55°C, with gentle shaking every 5 min. Densitometry analysis was performed as previously described (21) .
For immunoprecipitations, cell lysates were prepared and quantitated as described above.
The lysates were pre-cleared for 30 minutes at 4°C with the appropriate sepharose beads (Zymed Laboratories) conjugated with protein G or A prior to immunoprecipitation reactions. All beads were diluted and mixed for 1 hour at room temperature with an equal volume of Tris-buffered saline (50mM Tris, pH 7.5, 120mM NaCl) + 2.5 % milk prior to use. Following pre-clearing, lysates were aliquotted into microcentrifuge tubes, where an equal volume of lysate was used for each immunoprecipitation reaction. The volumes of each reaction were equalized to 500 µl with lysis buffer, 5µg of primary antibody was added, and the reaction was carried out at 4°C rotating end-over-end. The following day, the appropriate sepharose beads were added and the reaction was allowed to continue to rotate end-over-end at 4 °C for 90 min. The beads were then pelleted and washed three times with lysis buffer (+ protease inhibitors). Reducing sample buffer was added to each pellet, boiled for 5 min, centrifuged, and the supernatants loaded onto 6% NOVEX Tris/Gly (Invitrogen) gels for Western analysis. In Vitro Calpain and Caspase-3 Assay -E-cadherin was immunoprecipitated (as described above)
from LNCaP cell lysates with the C20820 antibody. After the third wash with lysis buffer (+ protease inhibitors), the supernatants were removed and the reactions placed on ice. The sepharose beads were then re-suspended in an appropriate volume of lysis buffer, and divided equally into five eppendorf tubes for five separate reactions. They were then centrifuged at 6,000 rpm for 3 minutes at 4 °C, the supernatants removed, and tubes placed on ice. For the calpain assay, the following proteolysis buffer was used at 25 µl per reaction: 100mM HEPES, 10mM
DTT, 10% glycerol (v/v), 1mM CaCl 2 . A separate buffer that contained 10mM EGTA was also used. Reactions were started by adding 0.4 units of µ-calpain, 0.95 units of m-calpain, or 50 units of caspase-3 (all from Calbiochem) and were carried out at room temperature. For the caspase-3 assay, the following proteolysis buffer was used at 25 µl per reaction: 100mM HEPES, 10mM
DTT, 10% glycerol (v/v), 1mM EGTA. Reducing sample buffer was added to each tube to stop the reaction at each time point. The reactions were boiled for 5 minutes and the supernatants were loaded onto 6% NOVEX Tris/Gly (Invitrogen) gels for Western analysis.
Mutagenesis -E-cadherin deletion mutants were generated using the Quikchange kit (Stratagene).
The parental plasmid was wild-type full-length human E-cadherin cloned into the pcDNA3 vector cDNA Microarray Analysis -Analysis of samples were performed as previously described (39) .
In brief, cDNA generated from prostate samples (i.e. prostate cancer) and benign prostate tissue (reference) samples were labeled with distinguishable fluorescent dyes and hybridized to the cDNA microarray (10,000 clones). The cDNA microarray was analyzed using a scanner, and fluorescence ratios were determined for each gene. Color intensities were converted into ratios of gene expression. These ratios are imported into a database for further analysis. To test for significant differences in the mean cDNA expression between all tissue types, we performed a one-way ANOVA test. To determine differences between all pairs (e.g., localized prostate cancer A Rapid Autopsy Protocol has been previously described (40) . Permission for an autopsy was granted from patients with hormone-refractory prostate cancer to participate in an IRBapproved tissue donor program at the University of Michigan. Metastases from prostate cancer were removed from the liver and immediately frozen in liquid nitrogen. The metastases were confirmed as prostate cancer in origin by a genitourinary pathologist (M.A.R.) at the University of
Results

Ionomycin Induces a Calpain-Dependent Cleavage of E-cadherin to 100-kDa -Previous studies
from our lab have shown that PKC activation induces a signal transduction pathway that leads to the truncation of E-cadherin in prostate and mammary epithelial cells (41, 42) . Activation of PKC has a number of physiological ramifications in the cell, including cell proliferation and differentiation, changes in gene expression, and transmembrane ion transport (43) . We
hypothesized that E-cadherin cleavage may be due to the influx of calcium ions initiated by PKC activation. To specifically address the role of calcium in the cleavage of E-cadherin, we treated
LNCaP cells with the calcium ionophore, ionomycin, and observed the rapid accumulation of a novel 100-kDa fragment of E-cadherin that was designated E-cad 100 (Fig. 1A, top panel) .
Ionomycin did not result in the accumulation of the previously described E-cadherin species, Ecad 97 . Due to the apparent role of calcium in E-cadherin cleavage, we speculated that the calciumdependent protease calpain may mediate the cleavage of E-cadherin. E-cadherin cleavage and the accumulation of E-cad 100 was dramatically inhibited in cells pre-treated with the calpain inhibitors calpain inhibitor I, calpain inhibitor II or calpeptin (Fig. 1A , top panel). These inhibitors had no effect on the generation of the 97-kDa species ruling out the possibility that calpain generates both fragments. E-cadherin cleavage to 100-kDa was also prevented by calpain inhibitor I following TPA treatment (data not shown).
To help confirm that ionomycin induced a calpain-mediated cleavage of E-cadherin, we reprobed the membranes with an α-spectrin antibody. α-spectrin is a well-documented calpain substrate with a molecular weight of 280-kDa that is cleaved by calpain to produce a 145-kDa/150-kDa doublet (33 Again, using the same membrane, we assayed for the autolysis of the large subunit of calpain by immunoblot (Fig. 1A, bottom panel) . Although faint, immunoblot analysis revealed a clear conversion of the 80-kDa large subunit to the 78-kDa active monomer following the addition of ionomycin. Pre-treatment of LNCaP cells with calpain inhibitor I, calpain inhibitor II, and calpeptin prevented this autolysis.
A similar experiment was performed using MCF-7 cells (Fig. 1B) . MCF-7 cells were pretreated with calpain inhibitor III and calpeptin prior to ionomycin treatment. Figure 1B shows that these inhibitors effectively blocked E-cadherin cleavage by ionomycin. Re-probing the membrane for α-spectrin shows that calpain inhibitor III and calpeptin blocked calpain-mediated spectrin cleavage ( Fig 1B, middle panel) . Although partial, re-probing with µ-calpain antibody showed some inhibition of autolysis of the µ-calpain large subunit (Fig. 1B, bottom panel) . We observed that calpain inhibitor 3 slightly reduced the amount of calpain; this may be an indirect effect of the inhibitor on calpain stability. Taken together, these data show that ionomycin treatment of LNCaP and MCF-7 cells induces a calpain-dependent truncation of E-cadherin to the 100-kDa form that was significantly inhibited by calpain inhibitors.
Calpain Cleaves E-cadherin In Vitro -To determine if purified calpain could generate E-cad 100 in vitro, we incubated E-cadherin immunopurified from untreated LNCaP cells with either µ-or m-calpain. In the presence of both isozymes, full-length E-cadherin was rapidly cleaved to the 100-kDa fragment, and this truncation could be completely inhibited by addition of the calcium chelator EGTA (Fig. 2 A and B) . In the absence of calpain, the 100-kDa product was not detected. Over the course of 20 minutes, some general degradation of E-cadherin was observed, which was unrelated to the effects of calpain cleavage of E-cadherin. These results provide compelling evidence that both µ-and m-calpain can specifically cleave mature E-cadherin to the 100-kDa fragment in vitro.
Examination of the cytoplasmic domain of E-cadherin revealed a potential caspase-3
cleavage site within residues 747 DTRD. Caspase-3 is a cysteine protease that is involved in proteolytic breakdown during the execution of apoptosis and has been implicated in the cleavage of E-cadherin (20) . We wanted to determine if E-cad 100 was generated by caspase-3. A similar in vitro assay was performed using purified caspase-3, which failed to demonstrate cleavage of Ecadherin to E-cad 100 (data not shown).
PKC activation induces E-cad 100 -We utilized the E-cad -/-mammary epithelial cell line SKBR3
(44) to exogenously express E-cadherin. We selected stable clones that expressed moderate to high levels of the 2X-myc tagged E-cadherin protein, which migrates at a slightly higher molecular weight of 130kDa (37) . Activation of PKC in these E-cad-expressing SKBR3 cells (termed SK-Ecad) revealed the rapid accumulation of E-cad 100 over a course of 12 hours (Fig. 3) .
PKC activation by TPA treatment did not induce expression of any endogenous E-cadherin protein in untransfected SKBR3 cells. We also noticed a dramatic increase in the expression levels of E-cadherin in the transfectants; however, the mechanism through which this up-regulation occurs is currently unclear, as the E-cadherin cDNA is driven by a CMV promoter and does not contain any phorbol-responsive elements. To address whether increased expression of E-cadherin was required for cleavage, LNCaP cells were pre-treated with cycloheximide prior to TPA treatment. Figure 4 demonstrates that blocking E-cadherin synthesis with cycloheximide did not 
Epitope and Functional
Mapping of E-cad100 -TPA-treated SK-Ecad cells were utilized to map the cleavage site on E-cadherin. The specific antibody epitopes that were used are shown in figure   5 . TPA-treated SK-Ecad cell lysates were immunoblotted with the different antibodies that recognized epitopes in either the extracellular or cytoplasmic domains of E-cadherin. E-cad 100 was recognized by the N-terminal antibody E-9, as well as by the cytoplasmic antibody 4A2, which has been mapped to residues 757-778, and by another cytoplasmic antibody C20820 which has been mapped to residues 773-791 (45). The antibody SC-1499 (46) that maps to the C-terminus of Ecadherin failed to recognize E-cad 100 (Fig. 5 ). Although three antibodies had variable sensitivities for E-cad 100 , the immunoblot data indicated that the cleavage site was in the cytoplasmic domain of E-cadherin located between the C20820 and SC-1499 epitopes.
To further verify the antibody mapping and to functionally map the truncation, we employed co-immunoprecipitations utilizing the catenin binding proteins to determine if the β-catenin, γ-catenin, and p120 binding domains are present in E-cad 100 . The β-catenin and γ-catenin binding domains have been mapped to residues 815-839 of the cytoplasmic domain of E-cadherin (47) . The p120 binding site has been mapped to residues 758-773 (48). We predicted that p120
would retain adhesiveness to E-cad 100 , while β-catenin and γ-catenin would not. Coimmunoprecipitations from TPA-treated LNCaP lysates revealed that only full-length E-cadherin is bound to these proteins (Fig. 6) . As a positive control, E-cadherin was also immunoprecipitated using a cytoplasmic antibody that recognizes E-cad 100 . The co-immunoprecipitation data demonstrate that E-cad 100 has lost the ß-and ?-catenin binding domains.
Mutation of the E-cadherin Cytoplasmic Domain Inhibits Truncation of E-cadherin In Vivo -
Based on the data from the immunoblot and co-immunoprecipitation experiments, the calpain cleavage site appeared to reside between the C20820 antibody epitope and the β-catenin binding domain. Examination of the amino acid sequence of E-cadherin between residues 773-815 revealed three potential calpain cleavage sites (Fig. 7A) . To identify the calpain cleavage site
within the E-cadherin cytoplasmic domain in vivo, we generated three E-cadherin deletion mutants targeted within the proposed region in the E-cadherin cytoplasmic domain (Fig. 7A) . In a pcDNA3 vector harboring the wild-type human E-cadherin cDNA, we engineered in-frame deletion mutants of 5 or 6 amino acids spanning the three potential calpain cleavage sites and transfected the constructs into SKBR3 cells. Stable pools were selected, and PKC was activated by TPA over a 24-hour time course. Two of the E-cadherin deletion mutants, SK-791∆5 and SK-795∆5 were truncated in an identical fashion as the wild type control, while deletion mutant SK-782∆6 exhibited complete inhibition of truncation (Fig. 7B ). These data indicate that amino acid residues 782-787 are essential for calpain cleavage as SK-782∆6 failed to be truncated in vivo.
Calpain is Upregulated in Localized and Metastatic Prostate Tumors -Both epigenetic and genetic mechanisms of E-cadherin inactivation have been demonstrated in adenocarcinoma (49).
We explored the possibility that calpain activity and expression may be associated with prostate tumorigenesis, and that E-cadherin cleavage may represent a novel mechanism of E-cadherin , respectively (one-way ANOVA, P < 0.001) (Fig. 8) . Pair-wise comparisons demonstrated significant differences in cDNA expression levels between clinically localized prostate cancer and metastatic prostate cancer with respect to benign prostate tissue (post-hoc analysis using Scheffé method, P < 0.01). Immunoblot analysis of E-cad 100 expression in matched normal and tumor prostate specimens revealed the appearance of E-cad 100 in the tumor aspect of the prostate gland compared to the normal (Fig. 9A) . Of 16 normal/tumor matched pairs examined, 6 showed an increase in E-cad 100 in the tumor aspect of the prostate gland compared to normal; two representative matched pairs are shown in figure 9 . The E-cad 100 species was also observed in prostate cancer liver metastases (Fig. 9B) . Multiple metastatic samples were harvested from the Liver, Diaphragm, Soft Tissue, Peritoneum, Adrenal Gland, and Paratracheal lymph node. The samples were analyzed by Western blot for E-cadherin, and each of the metastases demonstrated the presence of E-cad 100 (Fig. 9B) . Of over 40 prostate cancer metastases examined, virutally 100% contained the E-cad 100 species (data not shown). The abundance at which E-cad 100 was detected in localized and metastatic prostate cancer compared to normal prostate tissue correlated with the increase in m-calpain expression observed in the cDNA microarray. These data demonstrate that increased expression of calpain in prostate tumors is associated with the generation of the 100-kDa fragment in localized and metastatic disease.
Discussion
Results from the current study demonstrate that calpain induces a specific, inactivating proteolytic cleavage within the cytoplasmic domain of E-cadherin in prostate and mammary epithelial cells. Initial experiments indicated that cleavage of E-cadherin to the 100-kDa fragment was a calcium-dependent mechanism that implicated a number of calcium-regulated proteases.
Pre-treatment of LNCaP and MCF-7 cells with calpain inhibitors blocked the generation of ionomycin-induced E-cad 100 , strongly implicating calpain in this process.
In vitro experiments also supported the hypothesis that E-cadherin is a substrate for calpain. Both µ-and m-calpain effectively cleaved full-length E-cadherin in vitro to 100-kDa. We proceeded to characterize this truncation using the mammary epithelial cell line SKBR3, which do not express E-cadherin protein (44) . We showed that the truncation of exogenous E-cadherin to 100-kDa was rapidly induced by PKC activation in SKBR3 cells transfected with wild-type Ecadherin. We found that this truncation occurred in the cytoplasmic domain of E-cadherin, and that this truncated species of E-cadherin is unable to bind to β-catenin, γ-catenin, and p120, which are essential for the adhesive and cell signaling functions of E-cadherin (50). In our study E-cad 100 does not associate with p120; however, an association would be predicted from previous studies that have mapped the p120 binding site on E-cadherin (48) . One explanation is that cleavage of Ecadherin changes the protein conformation near the juxtamembrane domain, resulting in the loss of the p120 binding site.
An examination of the amino acid sequence of the cytoplasmic domain of E-cadherin revealed potential calpain cleavage sites that were targeted for mutation. The E-cadherin 782∆6 mutant failed to generate E-cadadjacent mutant sites were truncated in the same fashion as wild-type E-cadherin. While the calpain cleavage site may reside within residues 782-787 in the E-cadherin cytoplasmic domain, it is possible that the 782∆6 mutation has merely disrupted secondary structure or a calpain binding site that is required for cleavage. Based on our mutagenic analysis, we hypothesize that the residues 782-787 are either critical for calpain binding or represent the actual cleavage site.
Calpain has been implicated in the cleavage of other membrane-proteins involved adhesion, most notably members of the integrin family (34) . However, the precise function of calpain in cellular adhesion remains to be elucidated. Caspases are a well-studied family of cysteine proteases that act as the executers of apoptosis (51) . Caspase-3 has been shown to cleave E-cadherin during apoptosis (20) . However, we found that caspase-3, was not responsible for the specific cleavage of E-cadherin to generate the 100-kDa species (data not shown).
In a variety of adenocarcinomas, aberrations in E-cadherin expression have been noted in malignant transformation of epithelium, metastatic progression, and decreased patient survival (9, (52) (53) (54) . The development of metastatic prostate cancer is a multi-step process in which the disruption of cellular adhesion promotes both local invasion and distant dissemination. In prostate cancer the loss of E-cadherin function does not appear to result from allelic loss or gene mutation to any great extent but rather to other mechanisms, such as decreased transcription due to the aberrant methylation of its promoter (13) . Although important in the etiology of some cancers, genetic alteration and promoter methylation do not account for all of the physiologic mechanisms
by which E-cadherin function is abrogated during tumorigenesis.
The first reports of E-cadherin proteolysis emerged nearly two decades ago when it was discovered that a novel, 80-kDa fragment of E-cadherin was released into the culture media of mouse and human mammary tumor cells (16) . This proteolytic fragment, which was derived from the amino terminal, extracellular domain of E-cadherin was generated by a number of stress stimuli, such as serum deprivation and high calcium loading and was particularly intriguing due to its ability to disrupt the lateral adhesion of mammary epithelium. These findings were also of interest due to the fact this fragment was elevated in the serum of patients suffering from a variety of adenocarcinomas (55) . This laboratory has been involved in the characterization of proteolytic mechanisms that target and inactivate E-cadherin during prostate and mammary tumorigenesis and had previously demonstrated the generation of a novel, membrane bound fragment of Ecadherin that migrated at 97-kDa (E-cad 97 ) in prostate and mammary epithelial cells (41) . This fragment resulted from the truncation of E-cadherin in the cytosolic domain and had lost its ability to bind β-catenin thus abolishing the adherent function of the molecule. In a later study, we observed that the accumulation of E-cad 97 was significantly associated with localized prostate cancer as compared to adjacent normal tissue derived from the same prostate specimen (21) . We have since observed the presence of E-cad 100 , that while not as prominent as E-cad 97 in localized prostate cancer, appears to be present in all metastatic prostate tumors examined. We have also found that calpain is upregulated in localized and metastatic prostate tumors using cDNA microarray analysis and is the first report associating calpain with prostate tumorigenesis. Based on these observations, we hypothesized that specific proteolytic cleavage events, such as that mediated by calpain, target and inactivate E-cadherin. Such a loss of E-cadherin function may result in the net reduction of interepithelial adhesion and promote the malignant transformation of prostate epithelial cells. 
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